Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01470989 · ClinicalTrials.gov registry record · Phase 3
β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT01470989 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 136 participants.
The verdict
NCT01470989, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.
Interventions
- DRUG ACZ885
- DRUG Triamcinolone acetonide 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01470989
The ClinicalTrials.gov registry entry for NCT01470989 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ACZ885 is the first listed.
NCT01470989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01470989 about?
NCT01470989 is a clinical study titled "β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)". This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injec...
What is the current status of trial NCT01470989?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2011-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01470989?
The interventions under investigation include: ACZ885 (DRUG), Triamcinolone acetonide 40 mg (DRUG).
Who is sponsoring clinical trial NCT01470989?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.